1 and 5 year survival estimates for people with cirrhosis of the liver in England, 1998–2009: a large population study by Ratib, Sonia et al.
 
 
 
1 AND 5 YEAR SURVIVAL ESTIMATES FOR PEOPLE WITH CIRRHOSIS OF THE 
LIVER IN ENGLAND, 1998-2009: A LARGE POPULATION STUDY 
Sonia Ratib1, Kate M. Fleming 1, Colin J. Crooks1, Guruprasad P. Aithal2, Joe 
West1 
1Division of Epidemiology & Public Health, University of Nottingham, UK 
2NIHR Biomedical Research Unit in Gastrointestinal and Liver Diseases, Nottingham 
University Hospitals NHS Trust and University of Nottingham, Nottingham, UK 
 
Abbreviations: GPRD-General Practise Research Database; HES-Hospital Episode 
Statistics; ONS-Office of National Statistics; ICD10-International Classification of 
Disease 10th version, OPCS4-Office of Population Censuses and Surveys’ 
classification of interventions and procedures 4th version; UTS-Up to Standard. 
Word count: 5556 
Three tables and one figure 
Conflict of interest: None 
Financial support: University of Nottingham/National University Hospitals NHS 
Trust/National Institute for Health Research Senior Clinical Research Fellowship 
 
Correspondence: 
Sonia Ratib 
Division of Epidemiology and Public Health 
University of Nottingham 
Nottingham NG5 1PB, UK 
Tel: +44 (0)115 8231344 
Fax: +44 (0)115 8231946 
e-mail: sonia.ratib@nottingham.ac.uk 
  
 
 
ABSTRACT 
Background & Aims: Large, population-based studies that have included the full 
spectrum of cirrhosis estimating survival taking into account time-at-risk are lacking.  
We aimed to report 1- and 5-year average survival rates for people with cirrhosis to 
be used in a clinical and health care policy setting. 
Methods: We used the General Practice Research Database and linked English 
Hospital Episode Statistics to identify adult cases of cirrhosis from January 1998 to 
December 2009. We estimated 1- and 5-year survival according to whether time-at-
risk was entirely ambulatory or followed an emergency hospital admission related to 
liver disease, stratified by age, sex and aetiology to be used in a clinical setting. We 
used a multivariate Cox-proportional hazards model with emergency hospital 
admission as a time-varying variable adjusted for Baveno IV stage of cirrhosis at 
diagnosis. 
Results: We identified 5118 incident cases. Average survival probabilities at 1- and 
5-years were 0.88 (95% CI 0.87-0.90) and 0.74 (95% CI 0.72-0.77) for the 
ambulatory group and 0.56 (95% CI 0.54-0.58) and 0.30 (95% CI 0.29-0.32) 
following hospitalisation, respectively. A hospital admission at diagnosis or 
subsequently for liver disease substantially impaired prognosis independent of stage 
of cirrhosis (HR=4.11, 95% CI 3.70, 4.58).  
Conclusions:  Emergency hospitalisation for liver disease heralds a downturn in a 
patient’s outlook independent of their stage of cirrhosis. Our results provide 
population-based clinically translatable estimates of prognosis for the purposes of 
health care delivery and planning and communication to patients. 
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INTRODUCTION 
The prognosis of liver cirrhosis is only well described amongst non-representative 
groups of patients as previous studies were limited by geographical region [1-3], 
disease severity [4, 5] or to a specific aetiology such as viral hepatitis B [6, 7]. These 
studies are therefore of limited use in a clinical setting where patients with a range of 
aetiologies often ask about their prognosis, and they might also be misleading if 
used to advise how healthcare services should be tailored appropriately.  
One common limitation of previous large epidemiological studies was a restriction to 
either primary or secondary healthcare records [8, 9] preventing a truly non selective 
population-based approach. Consequently they have either not taken into account 
the large proportion of patients with cirrhosis who remain ambulatory with no 
hospitalisation, or alternatively the studies have failed to identify cirrhosis diagnosed 
during a fatal hospitalisation. Having an emergency hospital admission is not just 
associated with a deterioration in cirrhosis, but can be associated with and 
potentially the cause of a number of fatal complications such as pulmonary embolism 
[10]. No previous study has quantified the difference in survival between patients 
with cirrhosis who are managed without hospitalisations, and those who are 
managed following a hospitalisation. Without a comprehensive and heterogeneous 
population of people with cirrhosis that includes varying time-at-risk, it is impossible 
to quantify survival estimates which can be used in a clinical setting and describe the 
effect of hospitalisation for the full spectrum of disease.  
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The recent linkage of the General Practice Research Database with the Hospital 
Episode Statistics database and data from the Office for National Statistics has 
provided us with a novel opportunity to construct a study cohort that is representative 
of the whole population of people with cirrhosis in England. 
The aim of the study is to determine 1- and 5-year average survival of people with 
cirrhosis and the independent effect of hospitalisation while taking account of their 
age, sex, underlying aetiology and stage of disease.  
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METHODS 
Primary care data  
The General Practice Research Database (GPRD) is a longitudinal electronic 
database consisting of anonymised primary care records of over 10 million patients 
in the UK. Data are coded using the Read code system.  Participating practices are 
assigned an up to standard (UTS) date on completion of regular audits confirming 
data quality and completeness. The GPRD has previously been shown to be 
representative of the population of the UK [11]. 
Secondary care data  
The Hospital Episodes Statistics (HES) database comprises statutory records of all 
admissions (excluding out-patients) conducted in NHS trust hospitals and 
independent treatment centres in England. For each period of time under the care of 
a consultant, a patient is assigned a primary diagnosis and up to 19 secondary 
diagnoses, coded using the ICD10 (International Classification of Diseases, tenth 
revision), and/or up to 24 recorded procedures coded using the OPCS4 (Office of 
Population, Censuses and Surveys’ classification of interventions and procedures, 
fourth revision).  
Death registry data  
The Office for National Statistics (ONS) provides death registry data for GPRD 
practices that are linked to the HES database. Date of death from GPRD records 
was used where ONS date of death was unavailable. 
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Study population 
We had access to data from all 244 GPRD practices in England linked to HES 
between April 1997 and August 2010 and to the ONS between April 1998 and 
December 2010.  We defined cirrhosis in primary care if a person had a record 
containing a Read code for cirrhosis, oesophageal varices and/or portal hypertension 
in the GPRD. The Read code lists were adapted and updated from our previous 
externally validated definition [12] (Appendix1). We developed codes lists for 
cirrhosis diagnosis in secondary case from ICD10 (K70.3, K71.7, K72.1, K74.4, 
K74.5, K74.6, K76.6, I85.0, I85.9, I86.4, I98.2) and OPCS4 (J06.1, J06.2, T46.1, 
T46.2, G10.4, G10.8, G10.9, G14.4, G17.4, G43.7). 
Observation period  
The observation period commenced on the latest of (i) one year after the patient’s 
current registration date or (ii) the practice’s UTS date. The one year cut-off was 
used to avoid including potential prevalent cases, adapted from Lewis et al.’s 
methodology [13]. The period terminated on the earliest of (i) date of death, (ii) date 
the patient left the practice, or (iii) the practice’s last data collection date. We 
identified incident cases between 1st January 1998 and 31st December 2009. 
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Validating case definition 
For people with a cirrhosis diagnosis recorded in primary care we established how 
many had a hospital admission related to liver disease (e.g. alcoholic liver disease) 
(Appendix2). We identified whether the admissions were elective or emergency 
defined as per the NHS Information Centre definition [14]. 
For patients identified with cirrhosis from secondary care records only, we searched 
for evidence of liver disease in their healthcare records (Appendix3) and anywhere 
on their death certificate (Appendix4). We excluded patients who had a record of 
cancer and an isolated procedure relating to ascites and no other evidence or death 
related to liver disease. For the remaining patients we examined their primary care 
free text data for terms related to cirrhosis.  
Diagnosis date 
For each patient we assigned the date of diagnosis as the first date associated with 
a Read or ICD10/OPCS4 code for cirrhosis within the observation period. Patients 
younger than 18 years at diagnosis were excluded. 
Exposure of interest: Patient setting at diagnosis and in subsequent follow up. 
We categorised patients into three groups based on the patient setting:  
(1) Ambulatory at first diagnosis. These were patients who had a first record of 
cirrhosis in primary care or an elective admission in secondary care records. 
(2) Ambulatory with subsequent emergency hospital admission for liver disease: 
These were group (1) patients who had a subsequent emergency hospital admission 
related to liver disease.  
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(3) Hospitalised at first diagnosis: These were patients whose first record of cirrhosis 
occurred during an emergency hospital admission.  
 
Aetiology 
We searched the patient’s medical records for evidence of viral hepatitis, 
autoimmune and metabolic diseases. We defined patients as having an underlying 
alcoholic aetiology if there was mention in their records of alcoholism for example 
alcohol abuse, addiction or dependence, ‘problem drinking’ or referral to alcohol 
cessation services, or if their weekly alcohol consumption in their primary care 
records exceeded the Chief Medical Officer’s recommended amount (14 units for 
women, 21 units for men) [15]. Our Read code list for this was adapted from 
previous work [12] and our ICD10 code list was adapted from Statistics on Alcohol, 
England [16]. We also searched for evidence of viral hepatitis, autoimmune and 
metabolic diseases. Aetiology was ascribed in a hierarchical fashion of viral hepatitis, 
autoimmune or metabolic disease and alcoholic cirrhosis.  If a patient had no 
recorded aetiology they were ascribed a cryptogenic aetiology. 
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Stage of disease 
We defined stages of disease as agreed at the Baveno IV consensus conference 
[17]. Each of the four stages is defined by the presence or absence of certain clinical 
symptoms. Stages 1 and 2 represent compensated cirrhosis and stages 3 and 4 
decompensated cirrhosis.   
 
Statistical analysis 
We used death from any cause as the primary outcome in our study and excluded 
patients whose diagnosis date was concurrent with date of death. We tested for 
baseline differences between patient groups using chi-squared. Date of emergency 
hospital admission for liver disease was a time-varying variable, with follow-up split 
at this date to identify two groups based on  time-at-risk:  
(1) Patients in group 1 and group 2 (up to their emergency hospital admission date) 
contributed time-at-risk to the ambulatory group.  
(2) Patients in group 2 (followed-up from their emergency hospital admission date 
onwards) and group 3 contributed time-at-risk to the subsequent to hospitalisation 
group. 
We plotted a Kaplan-Meier survival curve to show the difference in survival by time-
at-risk and estimated survival probabilities (and 95% confidence intervals (CI)) 
overall and at 1- and 5-years. In order to determine how survival differed between 
the two time-at-risk groups we used Cox regression to estimate hazard ratios (HR) 
adjusting for potential confounders of age, sex, aetiology and stage of disease in our 
model.  The proportional hazards assumption was checked using log-log plots.  
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Clinically relevant interactions were tested with likelihood ratio tests. Stata version 12 
MP4 was used for all statistical analyses and a P-value<0.05 was taken as the cut-
off for statistical significance. 
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RESULTS 
Incident cases 
A total of 5247 people aged 18 and over were identified as incident cirrhosis cases 
between January 1998 and December 2009, 2965 from primary care records and an 
additional 2282 from secondary care.  129 (2.5%) patients whose date of diagnosis 
was concurrent with death were excluded, establishing an incident study cohort of 
5118 people diagnosed with cirrhosis during the observation period.  
Validation of case definition 
A total of 2975 cases were identified in primary care, 10 were excluded as they had 
a cirrhosis-related hospitalisation before 1998, 2721 (91.5%) were hospitalised 
during the observation period and 2230 (75%) had a diagnosis or procedure related 
to liver disease. Out of the 2282 patients with a record of cirrhosis in secondary care 
over 90.4% (n=2062) had either death or additional evidence related to liver disease 
in their records, or a confirmation of a cirrhosis diagnosis in their free text. 
Patient groups  
 2472 patients (48.3% of the incident cohort) were ambulatory at first diagnosis. Of 
these, 1648 (66.6%) remained ambulatory throughout the study period (group (1)) 
and 825 (33.4%) had a subsequent emergency hospital admission for liver disease 
(group (2)). 2646 patients had a first diagnosis during an emergency admission 
(group (3), 51.7%).   
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Patient characteristics 
The cohort of 5118 patients had a mean age of 59.3 (sd=14.3) years and slightly 
more men (57.9%) than women; just over half of the population had an aetiology of 
alcoholic cirrhosis (53.9%) (see Table 1). A higher proportion of men than women 
had alcoholic cirrhosis, 61.9% vs.42.8% respectively (
2
(3)
=235.7, P<0.001). Just 
over half of the study population (55.9%) had compensated cirrhosis (Baveno IV 
stages 1 or 2) at diagnosis. 
The distribution of age, sex, stage of disease and aetiology varied between the 
ambulatory and hospitalised at first diagnosis groups: the latter had a substantially 
lower proportion of people with alcoholic cirrhosis, almost twice the proportion of 
people with viral hepatitis (
2
(3)
=162.8, P<0.001), and a smaller proportion of men 
(
2
(1) 
=4.9, P=0.03) compared to the former.  The hospitalised at first diagnosis group 
had a higher proportion of younger patients than the ambulatory at first diagnosis 
group (
2
(4)
=33.5, P<0.001). A lower proportion of the ambulatory at first diagnosis 
group had decompensated cirrhosis (21.2% vs. 65.4%, 
2
(3)
=1000, P<0.001) than 
the hospitalised at first diagnosis group.  
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Survival  
In a total of 14,743 person-years of follow-up (median length of follow-up 1.97 [IQR 
0.42 to 4.39] years), there were 2565 (50.1%) deaths in our cohort. Overall the 
survival probabilities were 0.70 (95%CI 0.69-0.72) at 1-year and 0.47 (95% CI 0.45-
0.49) at 5-years. For the ambulatory group survival probabilities at 1- and 5-years 
were 0.88 (95% CI 0.87, 0.90) and 0.74 (95% CI 0.72, 0.77) respectively and 0.56 
(95% CI 0.54, 0.58) and 0.30 (95% CI 0.29, 0.32) respectively for the subsequent to 
hospitalisation group (see Figure 1).The Kaplan-Meier curve was truncated at 5 
years given that there was little follow-up time there onwards. 
Table 2 shows the survival probabilities at 5-years stratified by sex, time-at-risk, 
aetiology and age. They have been presented this way to provide prognostic 
information that could be applied easily in a clinical setting. Supplementary Table 2 
shows the equivalent 1-year survival probabilities. In general, survival decreased 
with age, was better for women and overall did not differ substantially between the 
different aetiologies, apart from a few instances. Supplementary Table 3 provides 
clinical examples that demonstrate how the survival estimates vary dependent on the 
clinical setting. 
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Multivariate analysis 
Adjusting for age, sex, aetiology and disease stage the risk of death was 
independently higher subsequent to hospitalisation compared to the ambulatory 
group (HR=4.11, 95% CI 3.70, 4.58). The risk of death in those with decompensated 
cirrhosis was only 1.2-fold that of patients with compensated cirrhosis (95% CI 1.11, 
1.31) adjusting for confounders. The multivariate Cox regression model is shown in 
Table 3. There was a statistically significant interaction between aetiology and age in 
the Cox regression model (
2
(12)
=26.4, P<0.001), adjusting for sex, stage of disease 
and time-at-risk group. Comparing the alcoholic with the cryptogenic patients there 
was approximately a two-fold risk of death in those younger than 45 years but no 
significant difference for patients older than 55 years. We report the adjusted hazard 
for each age-group by aetiology in Table 3.  
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DISCUSSION 
Main findings 
Our study is the first to use both primary and secondary healthcare linked data to 
establish a comprehensive cohort of people with incident cirrhosis in England and 
consequently to take into account the transition from ambulatory to hospitalised time-
at-risk when calculating accurate survival estimates. Our findings show that patients 
who remain entirely ambulatory have a 5-year survival of 74% which is comparable 
to that seen for cancer of the bladder [18]. In contrast, once a patient is hospitalised 
for an emergency their survival drops markedly. Indeed our findings suggest that 
emergency hospitalisation for liver disease heralds a downturn in a patient’s outlook 
independent of their stage of cirrhosis.  This we believe is important both for policy 
makers but also for clinical practice as we provide precise estimates of survival 
derived from an unbiased population that represents the generality of patients with 
cirrhosis.  These estimates, stratified by age, sex and aetiology can help with health 
care service provision planning but equally they can be used to communicate 
prognosis to patients based on a clinical assessment of disease and the natural 
history it undergoes.  In addition, using emergency hospitalisation as a risk factor is a 
pragmatic way of determining prognosis as it is objective and relatively easy to 
define. 
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Strengths and limitations 
The largest potential limitation with a study trying to determine incidence from 
routinely collected data is confidence in case definition.  Compared to previous 
studies which have used broad ICD10 code lists including non cirrhotic codes of 
K70.9 (alcoholic liver disease) and K74.3 (primary biliary cirrhosis) [19],  our 
definition of cirrhosis was much more restrictive.  The linked data have confirmed our 
case definitions by providing supporting evidence of liver disease among the various 
healthcare records and death registry, analogous to a chart review. Our current 
finding that a large proportion of patients diagnosed within the GPRD had a hospital 
admission related to liver disease (75%) emphasises the reliability of our case 
definition (given that we would not expect all cirrhotic patients to require a hospital 
admission). The finding falls in line with our previous external validation of primary 
care records where review of patients’ paper records confirmed cirrhosis in the 
majority of patient records checked [12]. In two recent systematic reviews case 
validity for most chronic conditions was described as good using the GPRD [20, 21]. 
In those presenting with cirrhosis in secondary care only, we found 90% had 
additional evidence of liver disease or death related to liver disease, or a mention of 
cirrhosis in their primary care written record. Kramer et al.[22] recently found ICD9 
codes for cirrhosis had a 90% positive predictive value and 87% negative predictive 
value.  Unlike the GPRD, HES data cannot be validated against medical records 
directly due to the annoymisation process used. A recent government audit found 
91% median accuracy [23] and our findings confirm accurate coding in the HES.  
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Overall we believe our case definition is as robust as previously reported in bespoke 
case studies of cirrhosis from secondary care.  That our population was not drawn 
from an individual tertiary referral centre is on its own a strength of the present study 
as the population is more representative of the entire spectrum of disease and is 
drawn from a population which is representative of the whole population of England 
[11]. 
Our group and others [24, 25] have shown previously that survival differs by disease 
stage i.e. compensated or decompensated cirrhosis.  The majority of patients 
classified as ambulatory were compensated at diagnosis (78.8%) whereas those 
who were hospitalised at first diagnosis were more likely to be decompensated 
(65.4%) as per the Baveno IV staging.  Our stratification into ambulatory or 
hospitalised onwards time-at-risk groups therefore perhaps reflects, to some extent, 
the transition from a compensated to decompensated state of disease.   By using the 
date of emergency hospital admission as a time-varying variable to define our time-
at-risk we have been able to add to our previous work, showing how those who 
initially present as ambulatory patients can have varied survival dependent on 
subsequent hospitalisation. Our study also highlights that irrespective of whether the 
patient had compensated or decompensated cirrhosis at first diagnosis, the key risk 
factor is having an emergency hospitalisation for liver disease. We cannot tease out 
from the data available what the exact cause of the hospital admission is and 
therefore are not able to speculate as to whether it is the liver disease per se or an 
event which occurs in hospital, which is affecting this difference in survival. 
Several studies have used the Model for End-stage Liver Disease (MELD) or Child-
Turcotte-Pugh scores [26, 27] to prognosticate survival for patients with cirrhosis and 
19 | P a g e  
 
determine whether transplantation is necessary. Although we have not reported 
these scores in our study, due to lack of laboratory data, the attraction of our method 
is its simplicity and independence of laboratory measurements in determining long-
term prognostic information. For those whom we could determine a MELD score 
(n=1415, 27.6%) Baveno IV stage of disease was shown to be highly correlated 
(p<0.001). We therefore took the pragmatic approach of using Baveno IV stage of 
disease to adjust our mortality estimates for disease severity as information on this 
variable was available for the entirety of our study population.  
We identified a record of alcohol use consistent with it being the underlying aetiology 
of disease in just over 50% of the patients. This is almost identical to that found 
previously in the UK and also in Scandinavia suggesting that if there is any 
underreporting it is likely to have been slight [3, 12, 28]. 
Finally, although we have ascertained the date of diagnosis and excluded prevalent 
individuals, the exact onset of a chronic disease process such as cirrhosis can’t be 
ascertained without a population based screening programme.  As there is no 
screening for cirrhosis in the National Health Service in England it is generally only 
diagnosed clinically when people first present to a healthcare provider.  Our study 
therefore is relevant to the pragmatic approach that is the reality in clinical practice. 
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Other literature   
Our mortality analysis can be compared in detail with two large hospital-based 
studies from England and Denmark. In 2005, Roberts et al. described the survival 
experience of 8192 people admitted to hospital with either chronic liver disease or 
cirrhosis in the Oxford region between 1968 and 1999. Our 1-year survival in the 
subsequent to hospitalisation group (56%) was lower than theirs (66.4%) and lower 
than that of the large Danish cohort study (65.5%) [3]. This is likely to be because 
our subsequent to hospitalisation group consisted of solely emergency admissions 
whereas the other two studies combined in- and out-patients.  The recent Danish 
study by Fialla et al.[2] separated in- and out-patients and reported 1-year survival 
for their out-patients as 76% which was lower than that of our ambulatory group 
(88%), most likely due to the fact that their out-patient group excluded ambulatory 
patients, a limitation highlighted by the authors.  
In comparison with our  previous study [25], survival at 1-year in the ambulatory 
group was almost identical to those who had compensated cirrhosis according to 
their primary care records (87.3%) while survival at 1-year in the subsequent to 
hospitalisation group was worse than the survival of those who had decompensated 
cirrhosis (75%). This demonstrates how survival of severely ill patients is over 
estimated if only primary care records are used.  
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Although some previous studies include patients with all aetiology types, their 
geographical bias might lead to non-representative populations in terms of aetiology. 
Our population-based approach has eliminated such bias, enabling our survival 
estimates to be applied to the full heterogeneity of the cirrhotic population. 
Most previous studies have found that those who had alcoholic cirrhosis had a worse 
prognosis than those without [8, 9]. We were also able to report how relative 
mortality between aetiology groups differs by age, information that has not previously 
been available. We showed aetiology affected prognosis in young patients but less 
so in older patients; comparing the alcoholic with the cryptogenic patients there was 
approximately a two-fold risk of death in those younger than 45 years but no 
significant difference for patients older than 55 years.
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  Conclusion  
In summary we have established a comprehensive, contemporary cohort, 
representing the whole spectrum of people with cirrhosis in terms of their mode of 
presentation and aetiology of disease. We have determined survival estimates for 
patients with different presentations of the disease and taken into account the 
transition from being ambulatory to becoming hospitalised. We have shown that an 
emergency hospitalisation predicts a poorer prognosis irrespective of disease stage, 
and conversely that patients have a relatively good outcome whilst ambulatory. This 
finding may influence the way doctors manage and monitor their patients in the 
future as, in the UK and elsewhere, when patients are diagnosed with cirrhosis a 
range of services are often implemented such as surveillance for hepatocellular 
carcinoma and oesophageal varices [29-31]. Some of these health care interventions 
may not be necessary or appropriate in certain patient groups, in particular those 
with a very poor prognosis.  Our results provide physicians as well as those planning 
health services with precise and unbiased estimates of survival which should help to 
allow optimisation of the allocation of limited resources. This may also allow 
evaluation of effectiveness of potential interventions that aim to reduce emergency 
admission among people with cirrhosis. 
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Table 1 Patient characteristics of the incident study cohort, 1998-2009 
 
 Males  Females  
Patient group Ambulatory 
at first 
diagnosis 
 
n=1393 
Hospitalised 
at first 
diagnosis 
 
n=1572 
Overall 
 
 
 
n=2965 
Ambulatory 
at first 
diagnosis 
 
n=1079 
Hospitalised 
at first 
diagnosis 
 
n=1074 
Overall 
 
 
 
n=2153 
Median f/up [IQR] 
Yrs* 
1.66 
[0.42, 3.82] 
1.15 
[0.14, 3.36] 
1.75 
[0.37, 4.11] 
2.35 
[0.85, 4.77] 
1.37 
[0.13, 3.69] 
2.25 
[0.55, 4.82] 
No. deaths (%) 
617 (44.3) 939 (59.7) 1556 (52.5) 375 (34.5) 634 (59) 1009 (46.9) 
No. with aetiology  
(%) 
Alcohol 758 (54.4) 1076 (68.4) 1834 (61.9) 355 (32.9) 567 (52.8) 922 (42.8) 
Viral hepatitis 
203 (14.6) 132 (8.4) 335 (11.3) 146 (13.5) 93 (8.7) 239 (11.1) 
Autoimmune/ 
Metabolic disease 105 (7.5) 78 (5) 183 (6.2) 210 (19.5) 112 (10.4) 322 (15) 
Cryptogenic 
327 (23.5) 286 (18.2) 613 (20.7) 368 (34.1) 302 (28.1) 670 (31.1) 
Mean age (sd) yrs 
59.2 (13) 57.9 (14.5) 58.5 (13.8) 61.3 (14.7) 59.4 (14.9) 60.3 (14.8) 
Age at diagnosis 
(%) yrs:  
<45 170 (12.2) 276 (17.6) 446 (15) 137 (12.7) 167 (15.6) 304 (14.1) 
45 to 54 
318 (22.8) 384 (24.4) 702 (23.7) 203 (18.8) 244 (22.7) 447 (20.8) 
55 to 64 
417 (29.9) 373 (23.7) 790 (26.6) 254 (23.5) 258 (24) 512 (23.8) 
65 to 74 
292 (21) 288 (18.3) 580 (19.6) 245 (22.7) 195 (18.2) 440 (20.4) 
 75 + 
196 (14.1) 251 (16) 447 (15.1) 240 (22.2) 210 (19.6) 450 (20.9) 
Baveno IV stage 
1 819 (27.6) 388 (24.7) 1207 (40.7) 652 (30.3) 286 (26.6) 938 (43.6) 
2 
269 (9.1) 163 (10.4) 432 (14.6) 207 (9.6) 78 (7.3) 285 (13.2) 
3 
178 (6) 649 (41.3) 827 (27.9) 149 (6.9) 472 (44) 621 (28.8) 
4 
127 (4.3) 372 (23.7) 499 (16.8) 71 (3.3) 238 (22.2) 309 (14.4) 
* Follow-up for the Ambulatory at first diagnosis is from time of diagnosis to end of follow-up or emergency hospitalisation (for 
those who had one). 
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Table 2 Survival probabilities (95% CI) at 5-years by sex, time-at-risk, aetiology and age 
 
 
Aetiology 
 
Males  Females  
Ambulatory 
n=1393 
Subsequent to 
hospitalisation 
n=2067 
Ambulatory 
n=1079 
Subsequent to 
hospitalisation 
n=1404 
Alcoholic  n=2756 
 
 
N= 
    
<45 yrs 0.79 (0.63, 0.89) 0.47 (0.39, 0.54) 0.87 (0.69, 0.95) 0.50 (0.39, 0.60) 
45 to 54 0.78 (0.68, 0.85) 0.39 (0.33, 0.45) 0.82 (0.70, 0.89) 0.35 (0.28, 0.43) 
55 to 64 0.70 (0.61, 0.77) 0.30 (0.25, 0.36) 0.79 (0.64, 0.89) 0.38 (0.31, 0.45) 
65 to 74 0.71 (0.60, 0.79) 0.21 (0.15, 0.27) 0.88 (0.73, 0.95) 0.21 (0.13, 0.31) 
 75+ 0.37 (0.19, 0.54) 0.07 (0.03, 0.13) 0.50 (0.24, 0.72) 0.16 (0.06, 0.29) 
Overall 0.70 (0.65, 0.74) 0.31 (0.28, 0.34) 0.79 (0.73, 0.85) 0.35 (0.31, 0.39) 
 
Viral hepatitis n=574 
    
<45 yrs 0.77 (0.59, 0.88) 0.39 (0.23, 0.55) 0.92 (0.54, 0.99) 0.54 (0.31, 0.72) 
45 to 54 0.92 (0.79, 0.97) 0.31 (0.19, 0.44) 0.87 (0.63, 0.96) 0.47 (0.27, 0.64) 
55 to 64 0.81 (0.62, 0.91) 0.44 (0.26, 0.61) 0.92 (0.57, 0.99) 0.34 (0.16, 0.53) 
65 to 74 0.65 (0.18, 0.90) 0 0.84 (0.61, 0.94) 0.25 (0.07, 0.49) 
 75+ 0.47 (0.15, 0.74) 0.06(0.03, 0.25) 0.61 (0.36, 0.79) 0.10 (0.02, 0.28) 
Overall 0.79 (0.70, 0.86) 0.31 (0.23, 0.38) 0.83 (0.73, 0.90) 0.36 (0.27, 0.46) 
 
Autoimmune/Metabolic 
disease n=505     
<45 yrs 0.83 (0.27, 0.97) 0.47 (0.15, 0.74) 1 0.91 (0.51, 0.99) 
45 to 54 1 0.32 (0.12, 0.54) 1 0.45 (0.24, 0.65) 
55 to 64 0.88 (0.57, 0.97) 0.25 (0.12, 0.41) 0.98 (0.84, 0.99) 0.57 (0.35, 0.74) 
65 to 74 0.82 (0.52, 0.94) 0.36 (0.17, 0.56) 0.86 (0.71, 0.94) 0.17 (0.08, 0.28) 
 75+ 0.65 (0.34, 0.84) 0 0.72 (0.48, 0.87) 0 
Overall 0.84 (0.72, 0.88) 0.28 (0.19, 0.37) 0.90 (0.83, 0.94) 0.28 (0.20, 0.36) 
 
Cryptogenic n=1283 
    
<45 yrs 0.81 (0.44, 0.94) 0.72 (0.48, 0.87) 0.93 (0.79, 0.98) 0.79 (0.62, 0.89) 
45 to 54 0.95 (0.81, 0.99) 0.49 (0.27, 0.68) 0.98 (0.84, 0.99) 0.42 (0.18, 0.65) 
55 to 64 0.74 (0.59, 0.84) 0.12 (0.04, 0.23) 0.85 (0.70, 0.93) 0.47 (0.30, 0.62) 
65 to 74 0.47 (0.33, 0.60) 0.18 (0.09, 0.30) 0.62 (0.48, 0.74) 0.26 (0.16, 0.37) 
 75+ 0.41 (0.25, 0.55) 0.10 (0.06, 0.16) 0.58 (0.48, 0.68) 0.12 (0.07, 0.19) 
Overall 0.61 (0.53, 0.68) 0.19 (0.14, 0.24) 0.72  (0.67, 0.78) 0.29 (0.24, 0.35) 
Total  
0.70 (0.66, 0.73) 0.29 (0.26, 0.31) 0.79 (0.76, 0.82) 0.33 (0.30, 0.36) 
CI=confidence intervals 
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Table 3: Multivariate cox regression model for n=5118 patients 
 Adjusted hazard ratios (95% CI)* P-value 
Time at risk: 
  Ambulatory 
  Hospitalised 
 
Ref 
4.11 (3.7, 4.58) 
 
 
<0.001 
Gender: 
   Male 
  Female 
 
Ref 
0.83 (0.76, 0.90) 
 
 
<0.001 
Age at diagnosis (%) yrs:  
  <45 
  45 to 54 
 55 to 64 
 65 to 74 
  75 + 
 
Ref 
1.78 (1.03, 3.09) 
3.34 (2.09, 5.35) 
4.53 (2.91, 7.05) 
6.94 (4.51, 10.7) 
 
<0.001 
Aetiology (%): 
  Cryptogenic 
  Alcohol 
  Viral hepatitis 
 Autoimmune/ 
  Metabolic disease 
 
Ref 
1.82 (1.17, 2.84) 
2.03 (1.23, 3.37) 
0.81 (0.36, 1.82) 
 
0.01 
Interaction age and aetiology 
<45 years 
  Cryptogenic 
  Alcohol 
  Viral hepatitis 
 Autoimmune/ 
  Metabolic disease 
45-54 years 
  Cryptogenic 
  Alcohol 
  Viral hepatitis 
 Autoimmune/ 
  Metabolic disease 
55-64 years 
  Cryptogenic 
  Alcohol 
 
 
Ref 
1.81 (1.17, 2.84) 
2.03 (1.23, 3.37) 
0.81 (0.55, 2.21) 
 
 
Ref 
1.46 (1.00, 2.11) 
1.36 (0.87, 2.06) 
1.28 (0.77, 2.14) 
 
Ref 
0.90 (0.72, 1.14) 
<0.001 
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  Viral hepatitis 
 Autoimmune/ 
  Metabolic disease 
65-74 years 
  Cryptogenic 
  Alcohol 
  Viral hepatitis 
 Autoimmune/ 
  Metabolic disease 
75+ years 
  Cryptogenic 
  Alcohol 
  Viral hepatitis 
 Autoimmune/ 
  Metabolic disease 
 
0.70 (0.49, 0.99) 
0.56 (0.38, 0.82 
 
 
Ref 
0.88 (0.73, 1.06) 
0.91 (0.65, 1.29) 
0.76 (0.57, 1.01) 
 
 
Ref 
0.99 (0.82, 1.18) 
1.03 (0.74, 1.43) 
0.92 (0.71, 1.20) 
Stage of disease: 
Compensated 
Decompensated 
 
Ref 
1.20 (1.11, 1.31) 
 
 
<0.001 
*Mutually adjusted for factors in table. CI=confidence intervals 
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Figure legends 
Fig. 1 Survival estimates within 5 years by time-at-risk group 
 
Number at risk is calculated at each point by excluding previous deaths and censored events 
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Supplementary Tables 
Table 1: Patient characteristics for Group2:  ‘Ambulatory with subsequent emergency admission for liver disease’  
 Males 
n=495 
Females 
n=330 
Median f/up [IQR] 
Yrs* 
1.04 
[0.15,  2.92] 
1.22 
[0.20,  3.16] 
No. deaths (%) 318 (64.2) 198 (60) 
No. with aetiology  (%) 
Alcohol 301  (60.8)  156 (47.3) 
Viral hepatitis 80 (16.2) 52 (15.8)  
Autoimmune/ 
Metabolic disease 42 (8.5) 67 (20.3) 
Cryptogenic 72 (14.5) 55 (16.7) 
Mean age (sd) yrs 59.1 (12.2) 60.7 (14.3) 
Age at diagnosis (%) yrs:  
<45 50 (10.1) 42 (12.7) 
45 to 54 124 (25.1) 66 (20) 
55 to 64 160 (32.3) 71 (21.5) 
65 to 74 100 (20.2) 90 (27.3) 
 75 + 61 (12.3) 61 (18.5) 
Baveno IV stage   
1 273 (55.2) 204 (61.8) 
2 87 (17.6) 44 (13.3)  
3 82 (16.6) 58 (17.6) 
4 53 (10.7) 24 (7.3) 
* Follow-up from date of emergency hospitalisation to end of follow-up 
 
 
 
 
 
 
 
34 | P a g e  
 
 
 
Table 2 Survival probabilities (95% CI) at 1-year by sex, time-at-risk, aetiology and age-group  
 
 
Aetiology 
 
Males  Females  
Ambulatory* 
n=1393 
Subsequent to 
hospitalisation¥ 
n=2067 
Ambulatory 
n=1079 
Subsequent to 
hospitalisation 
n=1404 
Alcoholic  
n=2756 
 
 
N= 
    
<45 yrs 0.89 (0.79, 0.95) 0.75 (0.69, 0.81) 0.91 (0.78, 0.97) 0.76 (0.67, 0.83) 
45 to 54 0.89 (0.83, 0.93) 0.64 (0.58, 0.69) 0.94 (0.87, 0.97) 0.66 (0.59, 0.73) 
55 to 64 0.85 (0.79, 0.89) 0.61 (0.56, 0.66) 0.92 (0.84, 0.96) 0.59 (0.51, 0.65) 
65 to 74 0.86 (0.79, 0.91) 0.47 (0.40, 0.53) 0.96 (0.86, 0.99) 0.53 (0.42, 0.62) 
 75+ 0.65 (0.52, 0.75) 0.31 (0.22, 0.40) 0.86 (0.66, 0.94) 0.30 (0.17, 0.45) 
Overall 0.85 (0.82, 0.87) 0.59 (0.56, 0.62) 0.92 (0.89, 0.95) 0.62 (0.58, 0.65) 
 
Viral hepatitis 
n=574     
<45 yrs 0.95 (0.83, 0.99) 0.69 (0.53, 0.81) 1.0 0.72 (0.49, 0.87) 
45 to 54 0.97 (0.88, 0.99) 0.56 (0.42, 0.68) 0.93 (0.74, 0.98) 0.77 (0.57, 0.88) 
55 to 64 0.98 (0.85, 0.99) 0.68 (0.48, 0.82) 1.0 0.63 (0.39, 0.79) 
65 to 74 0.94 (0.67, 0.99) 0.33 (0.13, 0.55) 0.97 (0.80, 1.0) 0.78 (0.46, 0.92) 
 75+ 0.81 (0.42, 0.95) 0.17 (0.03, 0.42) 0.73 (0.50, 0.87) 0.33 (0.11, 0.57) 
Overall 0.96 (0.91, 0.98) 0.57 (0.48, 0.64) 0.93 (0.87, 0.97) 0.67 (0.57, 0.75) 
 
Autoimmune/Metabolic 
n=505     
<45 yrs 1.0 0.92 (0.54, 0.99) 1.0 0.91 (0.51, 0.99) 
45 to 54 1.0 0.53 (0.27, 0.74) 1.0 0.70 (0.45, 0.85) 
55 to 64 0.96 (0.75, 0.99) 0.54 (0.27, 0.74) 1.0 0.75 (0.52, 0.88) 
65 to 74 1.0 0.60 (0.36, 0.78) 0.98 (0.89, 1.00) 0.54 (0.35, 0.69) 
 75+ 0.81 (0.52, 0.94) 0.23 (0.06, 0.47) 0.86 (0.71, 0.93) 0.38 (0.22, 0.55) 
Overall 0.96 (0.89, 0.98) 0.56 (0.45, 0.66) 0.96 (0.89, 0.98) 0.60 (0.50, 0.68) 
 
Cryptogenic 
n=1283     
<45 yrs 0.92 (0.72, 0.98) 0.79 (0.56, 0.90) 0.93 (0.79, 0.98) 0.82 (0.65, 0.91) 
45 to 54 0.95 (0.81, 0.99) 0.69 (0.45, 0.84) 0.98 (0.84, 2.00) 0.63 (0.39, 0.79) 
55 to 64 0.85 (0.74, 0.92) 0.28 (0.15, 0.42) 0.94 (0.84, 0.98) 0.57 (0.41, 0.69) 
65 to 74 0.74 (0.64, 0.82) 0.51 (0.39, 0.61) 0.84 (0.73, 0.91) 0.47 (0.36, 0.58) 
 75+ 0.74 (0.60, 0.82) 0.28 (0.21, 0.35) 0.76 (0.68, 0.83) 0.31 (0.24, 0.39) 
Overall 0.81 (0.76, 0.85) 0.40 (0.35, 0.45) 0.85 (0.81, 0.89) 0.47 (0.41, 0.52) 
Total  
0.86 (0.84, 0.88) 0.55 (0.53, 0.58) 0.91 (0.89, 0.92) 0.58 (0.55, 0.61) 
 CI=confidence intervals. 
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Table 3 Clinical examples of how survival estimates can be applied to different clinical settings 
Clinical example 1 
 
Clinical example 2 
 
Clinical example 3 
A 54-year old man, who only has minimal alcohol 
intake, is taken to A&E with haematemesis from 
oesophageal varices and diagnosed with cirrhosis of a 
non-alcoholic aetiology i.e. viral hepatitis. His 1- and 5-
year chances of survival are approximately 56% and 
31% respectively. A woman with a similar patient 
profile would have 1- and 5-year chances of survival of 
77% and 47% respectively. 
 
A 28-year old woman, who is a chronic alcohol drinker, 
has a palpable liver and jaundice and is referred by her 
GP to a hepatology clinic where she is diagnosed with 
cirrhosis. One year later she is taken to A&E with 
oesophageal bleeding. Her 1- and 5-year chances of 
survival are 76% and 50% respectively. By contrast a 
similarly aged woman who has cryptogenic cirrhosis 
and who is then admitted to hospital for her liver 
disease has a chance of survival of 82% at 1-year and 
79% at 5-years following hospitalisation. 
 
A 44-year old woman, who has a history of alcohol 
abuse has abnormal LFTs and is referred by her GP to 
a hepatology clinic where she is diagnosed with 
cirrhosis. Her 1- and 5-year chances of survival are 
91% and 87% respectively. A few months later she is 
admitted to hospital with haematemesis from 
oesophageal varices. Following this hospital admission 
her 1- and 5-year chances of survival, are reduced to 
76% and 50% respectively. 
 
 
